Market Cap 19.65M
Revenue (ttm) 1.20M
Net Income (ttm) -22.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,891.67%
Debt to Equity Ratio 0.05
Volume 187,400
Avg Vol 335,330
Day's Range N/A - N/A
Shares Out 31.15M
Stochastic %K 12%
Beta -0.35
Analysts Strong Sell
Price Target $7.15

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
Aawilliam2003
Aawilliam2003 Jul. 15 at 2:10 AM
$LGVN what is the value of the Aug readout? Since it’s only 12 months endpoint, that seems way to early for any real efficacy read. Even it it’s positive it does t mean much. Anyone disagree?
1 · Reply
Going4Blood
Going4Blood Jul. 14 at 9:33 PM
$LGVN When your company can't turn a profit, but the CEO just takes a pay raise increasing to half a million . . .
1 · Reply
Mangust05
Mangust05 Jul. 14 at 2:23 PM
$LGVN everything possible here . Imagine if they get approved. Could fly over $300🚀🚀🚀🥷
0 · Reply
gr8whitenorth
gr8whitenorth Jul. 14 at 4:54 AM
$LGVN the good ol days 🦍🚀🌚
0 · Reply
Dorps332
Dorps332 Jul. 13 at 3:19 PM
$LGVN doesn’t seem like the market cares about this stock anymore. Even with decent data it can’t move it
0 · Reply
sarah92
sarah92 Jul. 12 at 7:15 PM
$LGVN The company has received Rare Pediatric Disease and Orphan Drug designations for key programs, which can provide regulatory advantages..
1 · Reply
Orlandotrader
Orlandotrader Jul. 11 at 1:53 PM
$LGVN The Data Good!!! The Regulatory not Good. Another15 Million will be collected after Success. This will take them into Esrly 2027. New FDA meeting to Agree on Primary EndPoint. Will FDA Request phase 3 Trial? Most probable. Will need to find a Financial Backer.
1 · Reply
focafoca99
focafoca99 Jul. 8 at 8:21 PM
$LGVN granted special equity awards to its Executive Chairman for his role in the March 2026 financing transaction.
1 · Reply
Huskersnsaints
Huskersnsaints Jul. 7 at 2:36 PM
$LGVN Well evidently they are going to dilute this into a reverse split nothing else makes sense absolutely no upward movement No updates just share price erosion and at the same time reverse splits are most of these type of stocks business model as shareholders are the last concern to the companies management!!!!!!
1 · Reply
Kings124566
Kings124566 Jul. 7 at 3:16 AM
$LGVN explode or implode?
0 · Reply
Latest News on LGVN
Longeveron appoints Marie Washburn CFO

2026-07-06T20:10:28.000Z - 8 days ago

Longeveron appoints Marie Washburn CFO


Longeveron Transcript: AGM 2026

Jul 1, 2026, 11:00 AM EDT - 13 days ago

Longeveron Transcript: AGM 2026


Longeveron granted SME status by European Medicines Agency

2026-06-09T13:29:08.000Z - 5 weeks ago

Longeveron granted SME status by European Medicines Agency


Longeveron to Present at BIO International Convention 2026

Jun 4, 2026, 9:15 AM EDT - 5 weeks ago

Longeveron to Present at BIO International Convention 2026


Longeveron Proxy statement: Proxy filing

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Longeveron Proxy statement: Proxy filing


Longeveron Proxy statement: Proxy filing

May 20, 2026, 8:00 AM EDT - 7 weeks ago

Longeveron Proxy statement: Proxy filing


Longeveron reports Q1 EPS (19c) vs. (34c) last year

2026-05-13T21:35:38.000Z - 2 months ago

Longeveron reports Q1 EPS (19c) vs. (34c) last year


Longeveron Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Longeveron Earnings Call Transcript: Q1 2026


Longeveron Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Longeveron Quarterly report: Q1 2026


Longeveron Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Longeveron Earnings release: Q1 2026


Longeveron Slides: Investor presentation

May 13, 2026, 7:00 AM EDT - 2 months ago

Longeveron Slides: Investor presentation


Longeveron downgraded to Hold from Buy at Maxim

2026-05-11T15:43:29.000Z - 2 months ago

Longeveron downgraded to Hold from Buy at Maxim


Longeveron Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 2 months ago

Longeveron Proxy statement: Proxy filing


Longeveron Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 2 months ago

Longeveron Slides: Investor presentation


Longeveron Registration statement: Registration filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Longeveron Registration statement: Registration filing


Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:38:32.000Z - 3 months ago

Longeveron granted Chinese patent for potency assay methods


Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:27:11.000Z - 3 months ago

Longeveron granted Chinese patent for potency assay methods


Longeveron Slides: Investor presentation

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Longeveron Slides: Investor presentation


Longeveron price target lowered to $2 from $3 at Roth Capital

2026-03-18T23:20:16.000Z - 4 months ago

Longeveron price target lowered to $2 from $3 at Roth Capital


Longeveron Earnings Call Transcript: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Longeveron Earnings Call Transcript: Q4 2025


Longeveron Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Longeveron Earnings release: Q4 2025


Longeveron Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Longeveron Annual report: Q4 2025


Longeveron Slides: Investor presentation

Mar 17, 2026, 7:00 AM EDT - 4 months ago

Longeveron Slides: Investor presentation


3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 4 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC INKT


Longeveron prices 6.01M shares at 52c in private placement

2026-03-10T13:16:09.000Z - 4 months ago

Longeveron prices 6.01M shares at 52c in private placement


Longeveron Proxy statement: Proxy Filing

Mar 3, 2026, 7:00 AM EST - 4 months ago

Longeveron Proxy statement: Proxy Filing


Longeveron names Stephen Willard as CEO, succeeding Than Powell

2026-02-13T21:35:23.000Z - 5 months ago

Longeveron names Stephen Willard as CEO, succeeding Than Powell


Longeveron Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Longeveron Earnings Call Transcript: Q3 2025


Longeveron Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Longeveron Earnings release: Q3 2025


Longeveron Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Longeveron Quarterly report: Q3 2025


Longeveron Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 9 months ago

Longeveron Slides: Corporate Presentation


Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 11 months ago

Longeveron® Announces Key Leadership Updates


Longeveron Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Longeveron Earnings Call Transcript: Q2 2025


Longeveron Earnings release: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Longeveron Earnings release: Q2 2025


Longeveron Quarterly report: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Longeveron Quarterly report: Q2 2025


Longeveron Slides: Investor Presentation

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Longeveron Slides: Investor Presentation


Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 1 year ago

Longeveron Announces Up To $17.5 Million Public Offering


Longeveron Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing


Longeveron Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing


Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 1 year ago

Longeveron® Appoints Than Powell as Chief Business Officer


Longeveron Transcript: AGM 2025

Jun 13, 2025, 1:00 PM EDT - 1 year ago

Longeveron Transcript: AGM 2025


Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2025


Longeveron Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings Call Transcript: Q1 2025


Longeveron Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings release: Q1 2025


Longeveron Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Quarterly report: Q1 2025


Longeveron Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Slides: Q1 2025


Longeveron Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Proxy statement: Proxy Filing


Longeveron Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Proxy statement: Proxy Filing


Longeveron Registration statement: Registration Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing


Longeveron Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Longeveron Transcript: 37th Annual ROTH Conference


Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference


Longeveron Earnings Call Transcript: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q4 2024


Longeveron Earnings release: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings release: Q4 2024


Longeveron Annual report: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Annual report: Q4 2024


Longeveron Slides: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Slides: Q4 2024


Longeveron Transcript: Emerging Growth Conference 79

Feb 19, 2025, 3:10 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference 79


Longeveron Transcript: Biotech Showcase 2025

Jan 14, 2025, 7:00 PM EST - 1 year ago

Longeveron Transcript: Biotech Showcase 2025


Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025


Longeveron Transcript: Emerging Growth Conference77

Dec 5, 2024, 12:00 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference77


Longeveron Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q3 2024


Longeveron Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Quarterly report: Q3 2024


Longeveron Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings release: Q3 2024


Aawilliam2003
Aawilliam2003 Jul. 15 at 2:10 AM
$LGVN what is the value of the Aug readout? Since it’s only 12 months endpoint, that seems way to early for any real efficacy read. Even it it’s positive it does t mean much. Anyone disagree?
1 · Reply
Going4Blood
Going4Blood Jul. 14 at 9:33 PM
$LGVN When your company can't turn a profit, but the CEO just takes a pay raise increasing to half a million . . .
1 · Reply
Mangust05
Mangust05 Jul. 14 at 2:23 PM
$LGVN everything possible here . Imagine if they get approved. Could fly over $300🚀🚀🚀🥷
0 · Reply
gr8whitenorth
gr8whitenorth Jul. 14 at 4:54 AM
$LGVN the good ol days 🦍🚀🌚
0 · Reply
Dorps332
Dorps332 Jul. 13 at 3:19 PM
$LGVN doesn’t seem like the market cares about this stock anymore. Even with decent data it can’t move it
0 · Reply
sarah92
sarah92 Jul. 12 at 7:15 PM
$LGVN The company has received Rare Pediatric Disease and Orphan Drug designations for key programs, which can provide regulatory advantages..
1 · Reply
Orlandotrader
Orlandotrader Jul. 11 at 1:53 PM
$LGVN The Data Good!!! The Regulatory not Good. Another15 Million will be collected after Success. This will take them into Esrly 2027. New FDA meeting to Agree on Primary EndPoint. Will FDA Request phase 3 Trial? Most probable. Will need to find a Financial Backer.
1 · Reply
focafoca99
focafoca99 Jul. 8 at 8:21 PM
$LGVN granted special equity awards to its Executive Chairman for his role in the March 2026 financing transaction.
1 · Reply
Huskersnsaints
Huskersnsaints Jul. 7 at 2:36 PM
$LGVN Well evidently they are going to dilute this into a reverse split nothing else makes sense absolutely no upward movement No updates just share price erosion and at the same time reverse splits are most of these type of stocks business model as shareholders are the last concern to the companies management!!!!!!
1 · Reply
Kings124566
Kings124566 Jul. 7 at 3:16 AM
$LGVN explode or implode?
0 · Reply
nhyujm6
nhyujm6 Jul. 6 at 7:50 PM
$LGVN pivotal readout next month. Should move very fast very soon
0 · Reply
Huskersnsaints
Huskersnsaints Jul. 6 at 2:44 PM
$LGVN This is getting crushed, It's crazy that there just is no positive momentum with the approved product lines they have!!!! DESTROYING SHAREHOLDERS OF RECORD!!!!!
1 · Reply
Huskersnsaints
Huskersnsaints Jul. 2 at 6:08 PM
$LGVN does anyone have the idea of the execution of these companies product lines? Is the stock just dead or what it seems like it has so much going for it. It just will not move up.
2 · Reply
eastman71
eastman71 Jun. 25 at 3:29 PM
$LGVN I’d like you to say why you think it’s going to explode. Thanks.
0 · Reply
Kingdaley
Kingdaley Jun. 25 at 3:12 PM
$LGVN here is goes better get in
1 · Reply
Kingdaley
Kingdaley Jun. 25 at 3:10 PM
$LGVN about to explode soon
1 · Reply
odjfa
odjfa Jun. 25 at 7:28 AM
$LGVN $LGVN As a former bag holder, I feel bad for those still holding. 💎 Diamond hands
1 · Reply
BOUDIN420
BOUDIN420 Jun. 25 at 2:07 AM
$LGVN ww from .74
0 · Reply
Huskersnsaints
Huskersnsaints Jun. 24 at 8:06 PM
$LGVN This and scnx to great product line but for some reason the share price just gets destroyed every day crap stock move 100-1000% but this just drift lower every freaken day!!!!!
0 · Reply
Ueberschlaefer
Ueberschlaefer Jun. 24 at 3:35 AM
$LGVN is the company logo a human head and arm crawling out of a birth canal? is it like something to do with a live birth? or is it just a lab!@ with a cl!tor3s? who designed this? why?
0 · Reply
focafoca99
focafoca99 Jun. 18 at 1:32 PM
$LGVN present additional Phase 2a clinical data on laromestrocel at the AAIC poster session on July 13.
0 · Reply
HoldingontoPennies
HoldingontoPennies Jun. 17 at 3:45 PM
0 · Reply